Evidence map›Paper›PMID 28265792›Full record

ArticleBreast cancer research and treatment2017

Breast cancer screening in patients with cancers other than breast.

Robin B Leopold, Alexander W Thomas, Kyle F Concannon, Alissa D Correll, Catherine M LaPenta, Stephen M Maurer, Brian L Sprague, Sally D Herschorn, Claire F Verschraegen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Robin B LeopoldUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA.
Alexander W ThomasUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA.
Kyle F ConcannonUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA.
Alissa D CorrellUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA.
Catherine M LaPentaUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA.
Stephen M MaurerUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA.
Brian L SpragueUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA.
Sally D HerschornUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA.
Claire F VerschraegenUniversity of Vermont Cancer Center, 89 Beaumont Ave - Given E214, Burlington, VT, 05405, USA. claire.verschraegen@osumc.edu.
University of Vermont · US

Funding

Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
Vermont Screening Process Documentation UnitU54CA163303 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SPRAGUE, BRIAN L · 2011 to 2017
$6.4M
NCI NIH HHS P01 CA154292NCI NIH HHS U54 CA163303
6 · The paper itself

Abstract

backgroundScreening mammography can detect early breast cancers and reduce subsequent cancer mortality. However, there is a lack of consensus as to when to discontinue screening. The absence of clear-cut guidelines on when not to screen means that many patients with advanced malignancies continue screening despite unclear benefit.

methodsWe performed a retrospective cohort study of female patients diagnosed with a non-breast malignancy to explore the incidence and effects of screening mammography. Female patients diagnosed with a non-breast malignancy stage II or higher between 2007 and 2012 were identified through the Vermont Cancer Registry and cross-referenced with mammography screening logs from January 1, 2007 to September 30, 2014. Additional data were collected through chart review, in May 2016.

resultsTwenty-six percent of women (398/1501) with a stage II or greater cancer (other than breast) diagnosed between 2007 and 2012 had a screening mammogram within the first 5 years of their diagnosis. Of these 398 women, 193 (48.5%) were alive without cancer, 132 (33.2%) had died, and 73 (18.3%) were alive with cancer at the time of chart review. Of those who died, 84 (63.6%) had a stage III or IV cancer. Eighteen (4.5%) had a breast biopsy following a screening mammogram suspicious for cancer, resulting in 13 (3.3%) benign diagnoses and 5 (1.3%) breast cancer diagnoses. No patient died of breast cancer.

conclusionsExcept for highly curable cancers, female patients diagnosed with an advanced non-breast malignancy experienced mortality that outweighs a breast cancer mortality benefit from screening mammography as estimated from prior studies.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsEarly Detection of CancerFemaleHumansLung NeoplasmsMammographyMiddle AgedNeoplasms, Second PrimaryRetrospective StudiesYoung Adult

Identifiers

PMID28265792
PMCPMC5646383
OpenAlexW2594680221

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.